Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) generates frequent news across neuroscience and oncology, reflecting its focus on serious diseases such as sleep disorders, rare epilepsies, HER2-driven cancers and aggressive brain tumors. This news page aggregates company press releases and third-party coverage so readers can follow how Jazz’s clinical programs, marketed medicines and corporate actions evolve over time.
Visitors can expect updates on clinical trial results and data presentations for products like Epidiolex/Epidyolex (cannabidiol), Xywav (low-sodium oxybate), Ziihera (zanidatamab-hrii) and Modeyso (dordaviprone). Jazz regularly announces new Phase 3 and Phase 4 findings, real-world evidence analyses, and translational research presented at major meetings such as the European Epilepsy Congress, American Epilepsy Society Annual Meeting, World Sleep Congress, ASCO Gastrointestinal Cancers Symposium and the Society for Neuro-Oncology Annual Meeting.
News items also cover regulatory milestones, such as indications granted by the U.S. Food and Drug Administration and other health authorities, as well as designations like Breakthrough Therapy, Fast Track and Orphan Drug status for certain oncology assets. Corporate announcements may include executive appointments, board changes, investor webcasts, participation in healthcare conferences and legal or settlement updates disclosed in tandem with SEC filings.
For investors, clinicians and patients researching JAZZ, this page offers a centralized view of how Jazz Pharmaceuticals communicates progress in sleep medicine, epilepsy, oncology and neuro-oncology. By reviewing the news feed over time, readers can see how key programs advance from early data readouts through larger trials, regulatory interactions and post-approval evidence generation.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported a 39% increase in total revenues to $838.1 million for Q3 2021 compared to Q3 2020. Recently launched or acquired products contributed over 50% to net sales. Key highlights include strong adoption of Xywav, resulting in $153.1 million in sales, and a 21% revenue growth for Epidiolex at $160.4 million. The company raised its 2021 earnings guidance and decreased its net leverage ratio to 4.4x. However, GAAP net income showed a loss of $52.8 million per diluted share, contrasting with a profit of $148.2 million in the previous year.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present 16 new data abstracts at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. Key highlights include findings on Rylaze for acute lymphoblastic leukemia and Vyxeos for acute myeloid leukemia. The data showcases Jazz's commitment to improving treatments for rare blood cancers through collaborations and innovative trials. CEO Robert Iannone emphasizes the importance of these studies for developing new treatment options for patients.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will release its 2021 Q3 financial results on November 9, 2021, after U.S. market close. A live audio webcast is scheduled for 4:30 p.m. ET, with a replay available until November 16, 2021. The company is dedicated to innovating treatments for serious diseases, focusing on neuroscience and oncology. Interested parties can access the webcast through the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced a webcast scheduled for October 13, 2021 at 4:30 p.m. ET to update investors on Xywav, the FDA-approved treatment for idiopathic hypersomnia (IH) in adults, which received approval on August 12, 2021. Senior management will discuss commercial launch plans, alongside insights from sleep expert Dr. Richard Bogan. The webcast will be accessible via Jazz’s website, with a replay available for one week.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced its participation in two upcoming virtual investor conferences. The first event is the BofA Virtual Global Healthcare Conference on September 15, 2021, where the presentation will be accessible to registered attendees. The second is the Cantor Virtual Global Healthcare Conference on September 27, 2021, scheduled for 4:40 p.m. ET. An audio webcast will be available on their website, with a replay archived for a week.
Jazz Pharmaceuticals has received FDA approval for Xywav, a treatment for idiopathic hypersomnia in adults, marking it as the first medication specifically for this condition. With an estimated 37,000 diagnosed patients in the U.S., this approval opens access to a previously non-existent treatment. Xywav, previously approved for narcolepsy, demonstrated significant efficacy in clinical trials. The company plans to launch the product later this year, following necessary risk management implementations.
Stand Up To Cancer (SU2C) and Jazz Pharmaceuticals (NASDAQ: JAZZ) announced a three-year, $4 million research collaboration aimed at advancing treatment options for pediatric solid tumors and RAS-mutated cancers. The partnership will explore the clinical use of lurbinectedin in pediatric patients and pan-RAF inhibitors in resistant solid cancers. Additionally, it involves digital ethnography to understand treatment barriers in underserved communities. With an estimated 1.9 million new cancer cases in the U.S. in 2021, this initiative aims to expedite the delivery of innovative therapies.
GW Pharmaceuticals, now part of Jazz Pharmaceuticals (NASDAQ: JAZZ), announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved its cannabidiol as an adjunctive treatment for seizures associated with tuberous sclerosis complex (TSC) in patients aged two and older. This marks the fourth indication for GW's cannabis-based medicine in the UK. The approval is based on a Phase 3 study showing a 49% reduction in seizure frequency with cannabidiol, compared to 27% for placebo. GW will now seek reimbursement for eligible patients in the UK.
Jazz Pharmaceuticals (Nasdaq: JAZZ) reported Q2 2021 total revenues of $751.8 million, a 34% increase from Q2 2020. GAAP net loss was $363.3 million ($6.11 per share), while non-GAAP adjusted net income was $240.6 million ($3.90 per share). Net product sales of Xywav reached $124.2 million, significantly boosting the oxybate business. The company reaffirms 2021 revenue guidance of $3.02 billion to $3.18 billion. The GW acquisition strengthens R&D and commercial capabilities. Upcoming product launches include Xywav for idiopathic hypersomnia, enhancing growth prospects.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) has been added to the NCCN Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (ALL). This inclusion benefits both pediatric and adult patients who are hypersensitive to E. coli-derived asparaginase. Rylaze, FDA-approved on June 30, 2021, addresses the significant need for an effective asparaginase treatment. The NCCN Guidelines aid in treatment decision-making globally, enhancing patient care.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
